Clinical Trial: Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL



Official Title: A Single Arm Phase 2 Study of Y-90 SIRT in Combination With Durvalumab (MEDI 4736) and Gemcitabine/Cisplatin in Locally Advanced, Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Brief Summary:

This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery.

The specific names of the interventions that will be used are:

  • Y-90 (a type of radiation microsphere bead)
  • Durvalumab (a type of immunotherapy)
  • Gemcitabine (a type of chemotherapy)
  • Cisplatin (a type of chemotherapy)